Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome - PubMed (original) (raw)
Case Reports
Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome
Amanda Jagdis et al. Ann Allergy Asthma Immunol. 2014 Jul.
No abstract available
Similar articles
- Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis.
Kibsgaard L, Skjold T, Deleuran M, Vestergaard C. Kibsgaard L, et al. Acta Derm Venereol. 2014 May;94(3):363-4. doi: 10.2340/00015555-1687. Acta Derm Venereol. 2014. PMID: 24162824 No abstract available. - Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab.
Bell MC, Jackson DJ. Bell MC, et al. Ann Allergy Asthma Immunol. 2012 May;108(5):383-4. doi: 10.1016/j.anai.2012.02.021. Epub 2012 Mar 21. Ann Allergy Asthma Immunol. 2012. PMID: 22541416 Free PMC article. No abstract available. - Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy.
Paraskevopoulos G, Sifnaios E, Christodoulopoulos K, Mantopoulou F, Papakonstantis M, Sabaziotis D. Paraskevopoulos G, et al. Eur Ann Allergy Clin Immunol. 2013 Apr;45(2):52-5. Eur Ann Allergy Clin Immunol. 2013. PMID: 23821833 - The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.
Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M. Chang TW, et al. J Allergy Clin Immunol. 2015 Feb;135(2):337-42. doi: 10.1016/j.jaci.2014.04.036. Epub 2014 Jun 17. J Allergy Clin Immunol. 2015. PMID: 24948369 Review. - Use of omalizumab in the treatment of food allergy and anaphylaxis.
Lieberman JA, Chehade M. Lieberman JA, et al. Curr Allergy Asthma Rep. 2013 Feb;13(1):78-84. doi: 10.1007/s11882-012-0316-x. Curr Allergy Asthma Rep. 2013. PMID: 23065311 Review.
Cited by
- Human(ized) monoclonal antibodies in atopic patients - state of the art.
Yalcin AD, Onbasi K, Uzun R, Herth F, Schnabel PA. Yalcin AD, et al. Cent Eur J Immunol. 2020;45(2):195-201. doi: 10.5114/ceji.2020.97909. Epub 2020 Jul 27. Cent Eur J Immunol. 2020. PMID: 33456331 Free PMC article. Review. - Efficacy of Omalizumab in Indolent Systemic Mastocytosis.
Slapnicar C, Trinkaus M, Hicks L, Vadas P. Slapnicar C, et al. Case Rep Hematol. 2019 Sep 16;2019:3787586. doi: 10.1155/2019/3787586. eCollection 2019. Case Rep Hematol. 2019. PMID: 31637065 Free PMC article. - Successful treatment of idiopathic mast cell activation syndrome with low-dose Omalizumab.
Berry R, Hollingsworth P, Lucas M. Berry R, et al. Clin Transl Immunology. 2019 Sep 30;8(10):e01075. doi: 10.1002/cti2.1075. eCollection 2019. Clin Transl Immunology. 2019. PMID: 31576204 Free PMC article. - Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers.
Jimenez-Rodriguez TW, Garcia-Neuer M, Alenazy LA, Castells M. Jimenez-Rodriguez TW, et al. J Asthma Allergy. 2018 Jun 20;11:121-142. doi: 10.2147/JAA.S159411. eCollection 2018. J Asthma Allergy. 2018. PMID: 29950872 Free PMC article. Review. - Mast cell disorders: Protean manifestations and treatment responses.
Chen M, Kim A, Zuraw B, Doherty TA, Christiansen S. Chen M, et al. Ann Allergy Asthma Immunol. 2018 Jul;121(1):128-130. doi: 10.1016/j.anai.2018.03.027. Epub 2018 Mar 28. Ann Allergy Asthma Immunol. 2018. PMID: 29604336 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical